Showing results (401-410 of 654) with videos related to

Sort By:
Pageof 66
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Cold Spring Harbor Molecular Case Studies|January 5, 2017
ALK: a tyrosine kinase target for cancer therapyVijaykumar R Holla, Yasir Y Elamin, Ann Marie Bailey, et al.
Cancer|March 12, 2019
Clinical and molecular characterization of early-onset colorectal cancerAlexandra N Willauer, Yusha Liu, Allan A L Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing CancersTimothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Iranian Journal of Child Neurology|March 10, 2017
Frequency and Causes of Hypotonia in Neonatal Period with the Gestational Age of More Than 36 Weeks in NICU of Mofid Children Hospital, Tehran, Iran During 2012-2014Nosratollah Seyed Shahabi, Hossain Fakhraee, Mohammad Kazemian, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Annals of Surgery|January 25, 2006
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapyAnees B Chagpar, Lavinia P Middleton, Aysegul A Sahin, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trialKanwal P Raghav, Bettzy Stephen, Daniel D Karp, et al.
Scientific Reports|November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerTurcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid TumorsChristopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Pageof 66